Theratechnologies Inc. (TSE:TH - Free Report) - Equities research analysts at Leede Financial reduced their FY2025 EPS estimates for Theratechnologies in a research note issued to investors on Wednesday, February 26th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of $0.09 per share for the year, down from their prior estimate of $0.10. The consensus estimate for Theratechnologies' current full-year earnings is $0.03 per share. Leede Financial also issued estimates for Theratechnologies' FY2025 earnings at $0.09 EPS, FY2026 earnings at $0.21 EPS and FY2027 earnings at $0.33 EPS.
Separately, Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a report on Friday, February 14th.
Check Out Our Latest Report on Theratechnologies
Theratechnologies Trading Down 1.7 %
TSE TH traded down C$0.04 on Friday, reaching C$2.32. 25,719 shares of the company were exchanged, compared to its average volume of 52,712. The company has a current ratio of 1.08, a quick ratio of 0.64 and a debt-to-equity ratio of -293.92. The business's fifty day moving average price is C$2.50 and its 200 day moving average price is C$2.04. The stock has a market capitalization of C$74.02 million, a P/E ratio of -26.26, a price-to-earnings-growth ratio of -8.50 and a beta of 1.73. Theratechnologies has a fifty-two week low of C$1.59 and a fifty-two week high of C$3.13.
Theratechnologies Company Profile
(
Get Free Report)
Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.
Featured Stories
Before you consider Theratechnologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theratechnologies wasn't on the list.
While Theratechnologies currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
